RayKnowChina Research Map
Shortlist0

University of Science and Technology of China

中国科学技术大学

HefeiUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.08%Leads under 1 in 100 of China's research papers on NPC

Led 2 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.06%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025
ThemesEBV & screeningRadiotherapy techniqueRecurrent / metastatic disease

Hospitals counted here

  1. First Affiliated Hospital of USTC2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.7%Leads under 1 in 100 of China's research papers on ESCC

Led 19 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
6
Research papers it led
19
Trials it led
8
Share of China's trials
1.4%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 332025
ThemesRadiotherapyNeoadjuvant & combined treatmentImmunotherapy

Hospitals counted here

  1. First Affiliated Hospital of USTC17

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial.2025European journal of cancer (Oxford, England : 1990)
  2. Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients.2025BMC cancerFree full text
  3. Survival analysis of 80 elderly patients with esophageal squamous cell carcinoma receiving definitive concurrent chemoradiotherapy with S-1.2022Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
  4. Prognostic Significance of Platelet (PLT) and Platelet to Mean Platelet Volume (PLT/MPV) Ratio During Apatinib Second-Line or Late-Line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients.2022Technology in cancer research & treatmentFree full text
  5. Long non-coding RNA SNHG16 promotes tumor progression and cisplatin resistance in esophageal squamous cell carcinoma via miR-497-5p/HK2 axis.2025Journal of cardiothoracic surgeryFree full text
Trials on ClinicalTrials.gov6
  1. Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell CarcinomaRecruitingNCT07188103Lead sponsorPhase 2Start 2025-07
  2. Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical StudyNot yet recruitingNCT07034118Lead sponsorPhase 1Start 2025-08
  3. Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative RadioimmunotherapyRecruitingNCT06602843Lead sponsorN/AStart 2024-01
  4. Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and TislelizumabRecruitingNCT06408584Lead sponsorStart 2024-03
  5. Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal CarcinomaRecruitingNCT05937438Lead sponsorPhase 1/Phase 2Start 2023-09
  6. Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell CarcinomaRecruitingNCT05833594Lead sponsorStart 2023-07

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.7%Leads under 1 in 100 of China's research papers on HCC

Led 108 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
4
Research papers it led
108
Trials it led
9
Share of China's trials
0.6%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 332025
ThemesImmunotherapy & targeted drugsImaging, AI & early detectionRecurrence & prognosis

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of USTC91

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Spatial immune scoring system predicts hepatocellular carcinoma recurrence.2025Nature
  2. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.2021JAMA network openFree full text
  3. VCP downstream metabolite glycerol-3-phosphate (G3P) inhibits CD8+T cells function in the HCC microenvironment.2025Signal transduction and targeted therapyFree full text
  4. Disruption of tumor-intrinsic PGAM5 increases anti-PD-1 efficacy through the CCL2 signaling pathway.2025Journal for immunotherapy of cancerFree full text
  5. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.2023Journal of hepatology
Trials on ClinicalTrials.gov6
  1. Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular CarcinomaRecruitingNCT07793695Lead sponsorPhase 2Start 2026-09
  2. The Treatment of Liver Injury After Liver Resection With Polyene PhosphatidylcholineRecruitingNCT07150624Lead sponsorPhase 4Start 2025-11
  3. Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With EnvafolimabRecruitingNCT06498622Lead sponsorPhase 2Start 2024-07
  4. Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular CarcinomaRecruitingNCT07782632Lead sponsorStart 2019-01
  5. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  6. A Phase 2 Study of BB102 in Patients With Hepatocellular CarcinomaNot yet recruitingNCT07239986Study sitePhase 2Start 2025-12

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.3%Leads under 1 in 100 of China's research papers on Stomach cancer

Led 30 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
0
Research papers it led
30
Trials it led
2
Share of China's trials
0.1%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 0020242025: 002025
ThemesEarly detection & endoscopyPeritoneal spread & advanced diseaseSurgery

Hospitals counted here

  1. First Affiliated Hospital of USTC21

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Patient-Reported Outcome-Based Symptom Management Improves Quality of Life in Postoperative Gastroesophageal Cancer Patients: A Randomized Controlled Trial.2026OncologyRCT
  2. A WNT7B-m6A-TCF7L2 positive feedback loop promotes gastric cancer progression and metastasis.2021Signal transduction and targeted therapyFree full text
  3. Pretreatment lymphocyte-monocyte ratio (LMR) as a superior predictor of short-term progression outcomes in patients with gastric cancer receiving second- and later-line apatinib regimens.2023Journal of cancer research and clinical oncologyFree full text
  4. A Nomogram Combining Neutrophil-to-Lymphocyte Ratio and D-Dimer Predicts Chemosensitivity of Oxaliplatin-Based First-Line Chemotherapy in Patients with Unresectable Advanced Gastric Cancer.2022Technology in cancer research & treatmentFree full text
  5. Hand-assisted laparoscopic resection versus total laparoscopic gastric surgery for primary gastric gastrointestinal stromal tumors (GISTs): an analysis from a high-volume institution.2022BMC surgeryFree full text
Trials on ClinicalTrials.gov6
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  2. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  3. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  4. S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)RecruitingNCT03941561Study sitePhase 3Start 2019-01
  5. XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric AdenocarcinomaStatus unknownNCT03599778Lead sponsorPhase 1/Phase 2Start 2018-09
  6. Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric CancerStatus unknownNCT03334591Lead sponsorPhase 2Start 2017-10

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.5%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 11 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 332025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of USTC3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
1.1%Leads about 1 in 87 of China's research papers on Gastrointestinal stromal tumour

Led 6 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of USTC4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.4%Leads under 1 in 100 of China's research papers on Neuroblastoma

Led 5 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 2220242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of USTC4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.1%Leads under 1 in 100 of China's research papers on Myeloma

Led 2 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
2
Research papers it led
2
Trials it led
2
Share of China's trials
0.4%
Share of the world's papers
0.02%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025
ThemesDiagnosis, MRD & risk

Hospitals counted here

  1. First Affiliated Hospital of USTC2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.4%Leads under 1 in 100 of China's research papers on B-ALL New since 2021

Led 1 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
2
Research papers it led
1
Trials it led
5
Share of China's trials
2.0%
Share of the world's papers
0.09%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025
ThemesCAR-T & cell therapyMRD & relapseChildren

Hospitals counted here

  1. First Affiliated Hospital of USTC1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
0.5%Leads under 1 in 100 of China's research papers on Aplastic anaemia New since 2021

Led 2 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
1
Research papers it led
2
Trials it led
2
Share of China's trials
2.1%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025
ThemesStem cell transplantImmunosuppressive treatmentChildren

Hospitals counted here

  1. First Affiliated Hospital of USTC2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
0.4%Leads under 1 in 100 of China's research papers on Haemophilia A New since 2021

Led 1 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.04%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of USTC1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
0.2%Leads under 1 in 100 of China's research papers on NMOSD New since 2021

Led 1 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.05%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025
ThemesAntibodies & diagnosis

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
0.2%Leads under 1 in 100 of China's research papers on Myasthenia gravis

Led 1 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.04%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025
ThemesStandard immunotherapyAntibodies & diagnosis

Hospitals counted here

  1. First Affiliated Hospital of USTC1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
1.4%Leads about 1 in 71 of China's research papers on Moyamoya New since 2021

Led 5 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 1120242025: 002025
ThemesImaging & blood flowRevascularisation surgeryStroke & bleeding outcomes

Hospitals counted here

  1. First Affiliated Hospital of USTC5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
3.5%Leads about 1 in 29 of China's research papers on Wilson disease New since 2021

Led 7 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.0%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 2220242025: 112025
ThemesGenetics (ATP7B)Brain & movement symptomsLiver disease & transplant

Hospitals counted here

  1. First Affiliated Hospital of USTC6

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.6%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis New since 2021

Led 6 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 2220242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of USTC2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Celastrol-Ligustrazine compound proven to be a novel drug candidate for idiopathic pulmonary fibrosis by intervening in the TGF-β1 mediated pathways-an experimental in vitro and vivo study.2025Molecular diversity
  2. Co-Delivery of Astaxanthin and siTGF-β1 via Ionizable Liposome Nanoparticles for Improved Idiopathic Pulmonary Fibrosis Therapy.2024ACS applied materials & interfaces
  3. Mefloquine improves pulmonary fibrosis by inhibiting the KCNH2/Jak2/Stat3 signaling pathway in macrophages.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  4. Functional Au nanoparticles for engineering and long-term CT imaging tracking of mesenchymal stem cells in idiopathic pulmonary fibrosis treatment.2022Biomaterials
  5. CT/bioluminescence dual-modal imaging tracking of stem cells labeled with Au@PEI@PEG nanotracers and RfLuc in nintedanib-assisted pulmonary fibrosis therapy.2022Nanomedicine : nanotechnology, biology, and medicine
Trials on ClinicalTrials.gov5
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  3. A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary FibrosisTerminatedNCT06360094Study sitePhase 2Start 2024-08
  4. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Study sitePhase 2Start 2024-09
  5. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05321069Study sitePhase 3Start 2022-10

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.4%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis New since 2021

Led 3 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.05%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of USTC1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fabry disease

法布雷病
2.7%Leads about 1 in 36 of China's research papers on Fabry disease New since 2021

Led 2 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. First Affiliated Hospital of USTC2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led2
  1. Chest Discomfort, Left Ventricular Hypertrophy, Global T-Wave Inversion, and Short PR Interval Points to a Particular Cardiac Condition. What Could Be the Diagnosis?2025Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
  2. Coexistence of Fabry Disease and Membranous Nephropathy: A Case Report.2024Iranian journal of kidney diseases
Trials on ClinicalTrials.gov1
  1. A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseRecruitingNCT07187440Study siteStart 2025-11

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
0.0%Leads none of China's research papers on Primary biliary cholangitis

Led 0 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%
Trials on ClinicalTrials.gov2
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  2. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)Active, not recruitingNCT05896124Study sitePhase 2Start 2023-08

PubMed searchClinicalTrials.gov